TRPM8 Puts the Chill on Prostate Cancer
Laboratoire de Physiologie cellulaire, Inserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Université de Lille, 59655 Villeneuve d’Ascq Cedex, France
*
Author to whom correspondence should be addressed.
Academic Editors: Arpad Szallasi and Susan M. Huang
Pharmaceuticals 2016, 9(3), 44; https://doi.org/10.3390/ph9030044
Received: 26 May 2016 / Revised: 30 June 2016 / Accepted: 4 July 2016 / Published: 9 July 2016
(This article belongs to the Special Issue Transient Receptor Potential (TRP) Channels in Drug Discovery: Old Concepts & New Thoughts)
Prostate cancer (PCa) is one of the most frequently diagnosed cancers in developed countries. Several studies suggest that variations in calcium homeostasis are involved in carcinogenesis. Interestingly, (Transient Receptor Potential Melastatin member 8) TRPM8 calcium permeable channel expression is differentially regulated during prostate carcinogenesis, thereby suggesting a potential functional role for this channel in those cell processes, which are important for PCa evolution. Indeed, several studies have shown that TRPM8 plays a key role in processes such as the proliferation, viability and cell migration of PCa cells. Where cell migration is concerned, TRPM8 seems to have a protective anti-invasive effect and could be a particularly promising therapeutic target. The goal of this review is to inventory advances in understanding of the role of TRPM8 in the installation and progression of PCa.
View Full-Text
Keywords:
TRPM8; prostate cancer; migration
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Grolez, G.P.; Gkika, D. TRPM8 Puts the Chill on Prostate Cancer. Pharmaceuticals 2016, 9, 44.
Show more citation formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.